CarolynKMcCourtMD

Obstetrics & Gynecology • Saint Louis, MO

Gynecologic Oncology

Assistant Professor, Obstetrics and Gynecology, Brown University Program in Medicine

Join to view full profile

Dr. McCourt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McCourt's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 314-362-3181

Fax+1 314-362-2893

Education & Training

Washington University/B-JH/SLCH ConsortiumResidency, Obstetrics and Gynecology, 2001 - 2005
Creighton University School of MedicineClass of 2001

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 2014 - 2026
RI State Medical License 2005 - 2016
CT State Medical License 2008 - 2014
MA State Medical License 2008 - 2014
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Start of enrollment: 2010 Sep 07
Completed
Phase 2
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer Start of enrollment: 2011 Feb 01
Terminated
Phase 2
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18
Completed
Phase 3
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer Start of enrollment: 2018 Aug 08
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an-Mutated Tumor.
Carolyn K McCourt, Jacob Gross, Kevin Kalinsky, Ping Guan, Lisa M McShane
JCO Precision Oncology. 2025-03-01
1 citations
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomiz...
Matthew A Powell, David Cibula, David M O'Malley, Ingrid Boere, Mark S Shahin
Gynecologic Oncology. 2025-01-01
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák
Future Oncology. 2025-01-01

Journal Articles

Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer
Ian S Hagemann, Premal H Thaker, Carolyn K McCourt, Katherine C Fuh, David G Mutch, Andrea R Hagemann, Matthew A Powell, Clinical Cancer Research
Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer
Ian S Hagemann, Carolyn K McCourt, Matthew A Powell, Premal H Thaker, David G Mutch, Katherine C Fuh, Andrea R Hagemann, Clinical Cancer Research

Press Mentions

NCI-MATCH Cancer Trial Finds a Promising Signal for the AKT Inhibitor IpatasertibOctober 26th, 2022

Professional Memberships

American College of Obstetricians and Gynecologists
Fellow
American College of Surgeons - ACS
Member